October 5, 2023: Pfizer Inc. declared that ABRILADA, an interchangeable biosimilar of Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA). All approved uses of ABRILADA are covered by the interchangeable designation, which also includes some patients with psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
March 2, 2023: An ODAC meeting will be held by the U.S. Food and Drug Administration (FDA) to discuss the supplemental new drug application (sNDA) for LYNPARZA, which is intended to be used in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. AstraZeneca and Merck & Co., Inc., which are referred to as MSD outside of the United States and Canada, made this announcement. On marketed and experimental medications for use in cancer treatment, the ODAC offers the FDA unbiased, professional opinions and recommendations. Although the committee's recommendations are not legally binding, the FDA does take them into account.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5384
Published Date: Nov 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are surge in covid19 cases, rise in prevalence of irritable bowel, and growth in geriatric population.
The market size of prednisone is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024-2036.
The major players in the market are Pfizer Inc., Merck & Co., Inc., GSK plc, Sanofi, and others.
The skin allergies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.